0000000000181442

AUTHOR

Giovanni Vaccaro

showing 2 related works from this author

Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis

2020

Combination regimens have shown superiority over single agents in the adjuvant treatment of resected pancreatic cancer (PC), but there are no data supporting definition of the best regimen. This work aimed to compare the efficacy and safety of mFOLFIRINOX, gemcitabine+capecitabine, and gemcitabine+nab/paclitaxel in PC patients. A meta-analysis was performed for direct comparison between trials comparing combination regimens and gemcitabine monotherapy. Subsequently, an indirect comparison was made between trials investigating the efficacy and safety of mFOLFIRINOX, gemcitabine+capecitabine, and gemcitabine+nab/paclitaxel because of the same control arm (gemcitabine). A total of three studie…

OncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentReviewNeutropenialcsh:RC254-282Capecitabine03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePancreatic cancerInternal medicinemedicineChemotherapyMeta-analysi030212 general & internal medicineAdjuvantChemotherapybusiness.industryMFOLFIRINOXPancreatic cancerlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseGemcitabineRegimenMeta-analysisOncologyPaclitaxelchemistryAdjuvant Chemotherapy Meta-analysis MFOLFIRINOX Pancreatic cancer Systematic review030220 oncology & carcinogenesisSystematic reviewbusinessAdjuvantmedicine.drug
researchProduct

167P Role of the multi-gene panel testing for detection of pathogenic variants in patients with hereditary bilateral breast cancer

2021

Oncologymedicine.medical_specialtyOncologybusiness.industryInternal medicineMedicineIn patientHematologybusinessBilateral breast cancerMulti geneAnnals of Oncology
researchProduct